Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab

This publication has 10 references indexed in Scilit:

• Elimination of Non-Viable cells by DNase Treatment Prior to Lymphocytotoxicity Test
  Tissue Antigens, 2008
• Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1
  Transplantation, 2004
• Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis
  Transplantation, 2002
• Improved specificity and sensitivity when using pronase-digested lymphocytes to perform flow-cytometric crossmatch prior to renal transplantation
  Transplant International, 2002
• Treatment of humoral rejection with rituximab
  The Annals of Thoracic Surgery, 2002
• IMPROVED FLOW CYTOMETRIC DETECTION OF HLA ALLOANTIBODIES USING PRONASE
  Transplantation, 2001
• The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatch
  Transplant International, 1995
• Chapter 7 Flow Cytometry Crossmatching for Solid Organ Transplantation
  Published by Elsevier ,1994
• THE FLOW CYTOMETRIC CROSSMATCH
  Transplantation, 1989
• Significance of the Positive Crossmatch Test in Kidney Transplantation
  New England Journal of Medicine, 1969